With 0.58 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.33 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.55 whereas the lowest price it dropped to was $9.2334. The 52-week range on ATXS shows that it touched its highest point at $16.90 and its lowest point at $5.94 during that stretch. It currently has a 1-year price target of $26.43. Beta for the stock currently stands at 0.68.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATXS was down-trending over the past week, with a drop of -1.55%, but this was up by 1.93% over a month. Three-month performance dropped to -23.84% while six-month performance rose 5.54%. The stock gained 52.81% in the past year, while it has gained 23.96% so far this year. A look at the trailing 12-month EPS for ATXS yields -2.09 with Next year EPS estimates of -1.80. For the next quarter, that number is -0.45. This implies an EPS growth rate of 29.93% for this year and -6.25% for next year.
Float and Shares Shorts:
At present, 56.43 million ATXS shares are outstanding with a float of 48.26 million shares on hand for trading. On 2024-11-29, short shares totaled 3.15 million, which was 557.0 higher than short shares on 1730332800. In addition to Ms. Jill C. Milne Ph.D. as the firm’s Co-Founder, CEO, President & Director, Mr. Noah C. Clauser CPA serves as its CFO & Treasurer.
Institutional Ownership:
Through their ownership of 1.01596 of ATXS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ATXS reported revenue of $0.0 and operating income of -$29014000.0. The EBITDA in the recently reported quarter was -$29014000.0 and diluted EPS was -$0.42.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATXS since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATXS analysts setting a high price target of 35.0 and a low target of 16.0, the average target price over the next 12 months is 26.42857. Based on these targets, ATXS could surge 267.65% to reach the target high and rise by 68.07% to reach the target low. Reaching the average price target will result in a growth of 177.61% from current levels.
Analysts have provided yearly estimates in a range of -$1.50045 being high and -$1.7882 being low. For ATXS, this leads to a yearly average estimate of -$1.69571. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
